Antimicrobial Development in the Era of Emerging Resistance

Title: Antimicrobial Development in the Era of Emerging Resistance

Volume: 9 Issue: 8

Author(s): Antonio Sorlozano, Cristina Carrasco, Jose Cabeza, Enrique Villegas and Jose Gutierrez

Affiliation:

Keywords: Faropenem, dalbavancin, telavancin, oritavancin, ceftobiprole, iclaprim

Abstract: Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.

Cite this article as:

Sorlozano Antonio, Carrasco Cristina, Cabeza Jose, Villegas Enrique and Gutierrez Jose, Antimicrobial Development in the Era of Emerging Resistance, Mini-Reviews in Medicinal Chemistry 2009; 9(8) . https://dx.doi.org/10.2174/138955709788681564